Reason that dopamine itself is not used to treat in Parkinson's disease:

A. While levodopa acts as a dopamine precursor and eventually increases dopamine at central D2 receptors, the reason dopamine itself is not used is not related to receptor affinity. Levodopa is chosen for its ability to cross the blood-brain barrier (BBB) and then be converted to dopamine, effectively restoring central dopaminergic activity. Dopamine itself would not reach the brain to act on these receptors. B. Parkinson’s disease is primarily a dopaminergic disorder, resulting from degeneration of dopamine-producing neurons in the substantia nigra. Although there is an imbalance between dopamine and acetylcholine, the underlying problem is not cholinergic in nature. Treating with dopamine directly would target the core deficit, but it is ineffective due to pharmacokinetic limitations. C. Dopamine cannot be used to treat Parkinson’s disease because it cannot cross the blood-brain barrier. The BBB selectively blocks many substances from entering the central nervous system, including dopamine. Administering dopamine orally or intravenously would only increase peripheral dopamine levels, causing side effects such as nausea, vomiting, hypotension, or cardiac arrhythmias, without improving CNS function. Levodopa, a metabolic precursor of dopamine, crosses the BBB, enters the CNS, and is then converted to dopamine, effectively replenishing the deficient neurotransmitter and improving motor symptoms. D. The cost of dopamine is not the reason it is not used; the pharmacologic limitation of BBB impermeability is the key issue. Levodopa provides a practical, effective, and safe method of increasing central dopamine.